The Swiss domestic pharmaceutical market recorded a 5% increase in revenues of CHF8.1 billion at factory prices, last year. +Get the most important news from Switzerland in your inbox Turnover expansion was held back 2.4% by price reductions enforced by the government, reported trade association Interpharma. + Read our extensive coverage drug prices and insurance supply chains Of the total amount, almost CHF7.1 billion was paid by health insurance companies. The main driver of the growth in volumes was demographic developments and the resulting increase in demand for medical services. Interpharma emphasises that the 2.4% dampening effect, resulting from cuts by the Federal Office of Public Health (FOPH), accounted for the entire cost of introducing new drugs and extending existing approvals. + The high stakes fight over drugs prices Last year, the FOPH reduced the prices of almost 300 medicines by an average of 12%. Meanwhile, the rise of equivalent medicines continues. Generics ...
